Valsartan reduces atrial fibrillation in patients with heart failure
Rebecca Ireland
This article has no abstract so we have provided the first paragraph of the full text.
Atrial fibrillation (AF) occurrence is generally considered to worsen the prognosis of patients with heart failure (HF), and recurrence following AF treatment is very common. Cardiac remodeling is thought to be a major contributory factor. The Valsartan Heart Failure Trial (Val-HeFT) investigated the use of the angiotensin-receptor blocker valsartan in addition to normal therapy in patients with HF.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Opn: key regulator of pDC interferon productionNature Immunology News and Views (01 May 2006)
